Balancing Lemtrada’s Risk Versus Rewards
There’s been a lot of risk versus rewards chatter on social media following the recent decision by the European Medicines Agency to initiate a safety review of Lemtrada (alemtuzumab). The EMA has restricted use of the medication within the European Union while that review is underway. That’s worrying some people who are using Lemtrada or who are about to start. For me, it’s really a question of risks versus rewards. The EMA…Continue Reading